The Emergence of Cancer Vaccines: Reframing Value Demonstration, Pricing, and Access
In a recent article published on Pharmaceutical Executive, we look at the Emergence of Cancer Vaccines: Reframing Value Demonstration, Pricing, and Access
Developing a Successful Biopharmaceutical Pricing & Market Access Strategy, register now
Registration is now open for the 2026 “Developing a Successful Biopharmaceutical Pricing & Market Access Strategy” executive education programme, a collaboration between Windrose Consulting Group and the University of Cambridge MPhil in Bioscience Enterprise (MBE).
Timothy Rhee joins Windrose US
Windrose Consulting Group is pleased to welcome Timothy Rhee to our US office as an Analyst.
New team members in the UK
Windrose Consulting Group is delighted to welcome four new colleagues to our UK office: Shuang Wen, Devaki Jayal, Ahmed El Shafey, and Anoud Naeem.
Windrose Consulting Acquires Zenith Access Network
Windrose Consulting Group has acquired Zenith Access Network, a leading market access consultancy specializing in Greater China and emerging Asia-Pacific (APAC) markets
Novel Health Technology Assessment (HTA) Guidelines in Abu Dhabi
Innovative pharmaceutical products are constantly seeking access to developed and emerging markets across the globe, but gaps in clinical evidence and limited real-world data often leave uncertainty around their true value and impact on health and societal benefits.
Joint Clinical Assessment in Europe: What is the Advice for Pharma Companies After 10 Months?
After 10 months of Joint Clinical Assessment (JCA) is it possible to identify some early advice for pharma companies?
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
In a recent article published on Pharmaceutical Executive, we explore The Most-Favored-Nation Policy; it’s Outlook and Implications Beyond U.S.
Windrose Consulting Group Celebrates Seven Team Promotions
We’re thrilled to announce the promotion of seven outstanding team members at Windrose Consulting Group.
New team members in the US, Swiss, and UK offices
Windrose Consulting Group is delighted to welcome new team members to our US, UK and Switzerland offices.
Key Proposal to Include NRDL Category C for Innovative Therapies
The National Reimbursement Drug List (NRDL) has long been a critical vehicle for pharmaceuticals in China, providing patient access to treatments through centralized public insurance.
Navigating Brand-Brand Combinations Complexity:
“Brand-brand” combination therapy launches have become an increasingly popular strategy for manufacturers looking to maximize the value of their successful monotherapy launches.
Alessandro Goldaniga joins Windrose Switzerland
Windrose Consulting Group is delighted to welcome Alessandro Goldaniga, who has joined our Swiss Office as a Principal.
Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS Endpoints
In a recent article published on Pharmaceutical Executive, Anais Frappe and Mattia Belloni explore the role of non-OS endpoints, and advocate for a more systematic and balanced recognition of these endpoints, alongside OS, in HTAs.
Mark Kohler promoted to Senior Principal
Windrose Consulting Group Announces the Promotion of Mark Kohler to Senior Principal
Potential Impact of the Inflation Reduction Act
Download the report to find out about the Potential Impact of the Inflation Reduction Act.
New team members in the UK and Switzerland
Windrose Consulting Group is delighted to welcome two new team members to our UK and Switzerland offices.
Gordon Bache joins Windrose as Partner
Windrose Consulting Group is thrilled to welcome Gordon Bache as a Partner in our London, UK office.
Twelve Well-Deserved Promotions at Windrose
We’re thrilled to announce the promotion of twelve outstanding team members at Windrose Consulting Group.
Sam Symons joins US office
Windrose Consulting Group is pleased to welcome Sam Symons to our US office as an Analyst.